Global News

BioLineRx, I-Bridge Capital establish China joint venture

Friday, August 26, 2016

BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. 

[Read More]

Evofem enrolls first patient in Amphora Gel vaginal Ph trial

Friday, August 26, 2016

Evofem, a biotechnology company focused on the development and commercialization of women’s health products, has announced that patient enrollment has begun in their clinical study that will evaluate the effect and duration of Evofem’s proprietary vaginal gel, Amphora for bacterial vaginosis (BV), on vaginal pH.

[Read More]

Boehringer, Duke collaborate on IPF patient registry

Friday, August 26, 2016

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

[Read More]

Biomedical Systems, Foundry Health partner for real-time data access

Tuesday, August 23, 2016

Biomedical Systems, a 40-year-old, family-owned, clinical trial provider to pharmaceutical, medical device, biotech and CROs, has announced a new partnership with digital health company Foundry Health of Chicago. The two companies will collaborate on the development of a proprietary cloud-based data management system that will allow sponsors immediate access to clinical trial data in real time.

[Read More]

Cytori Therapeutics receives Frost & Sullivan 2016 Technology Innovation Award

Tuesday, August 23, 2016

Cytori Therapeutics has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of regenerative medicine for over a decade. Frost & Sullivan’s industry research and benchmarking analysis report that Cytori’s pioneering technology platform has become the leading technology to enable the research and practice of cellular therapies that harness the potential of stem and regenerative cells from adipose tissue.

[Read More]